Correspondence 0001493152-24-014568 from Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics, Inc.
Date: April 15, 2024 · CIK: 0001855485 · Accession: 0001493152-24-014568

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276741

Date

April 15, 2024

Author

Chief

Form

CORRESP

Company

Calidi Biotherapeutics, Inc.

Letter

Executive Drive, Suite 200,

San Diego, California 92121

April 15, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Attention: Tyler Howes

Re:

Calidi Biotherapeutics, Inc.

Registration Statement on Form S-1 (File No. 333-276741)

Withdrawal of Request for Acceleration

Ladies and Gentlemen:

The undersigned hereby respectfully requests that the Company’s letter of acceleration submitted on April 10, 2024, originally requesting that its Registration Statement on Form S-1 (File No. 333-276741) be accelerated to become effective at 5:30 p.m., Eastern Time, on April 11, 2024, as orally postponed to April 12, 2024, be withdrawn.

If you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.

Very
Truly Yours,
Calidi
Biotherapeutics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

4475
Executive Drive, Suite 200,

San
Diego, California 92121

April
15, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Tyler Howes

    Re:

    Calidi
    Biotherapeutics, Inc.

    Registration
    Statement on Form S-1 (File No. 333-276741)

    Withdrawal
    of Request for Acceleration

Ladies
and Gentlemen:

The
undersigned hereby respectfully requests that the Company’s letter of acceleration submitted on April 10, 2024, originally requesting
that its Registration Statement on Form S-1 (File No. 333-276741) be accelerated to become effective at 5:30 p.m., Eastern Time, on April
11, 2024, as orally postponed to April 12, 2024, be withdrawn.

If
you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at
(415) 262-8508.

    Very
    Truly Yours,

    Calidi
    Biotherapeutics, Inc.

    By:

    /s/
    Andrew Jackson

    Name:

    Andrew
    Jackson

    Title:

    Chief
    Financial Officer

SecProbe.io